News | Structural Heart | May 29, 2020

Neovasc Files CE Mark for Tiara TA Transapical Mitral Valve Replacement System

Neovasc Files CE Mark for Tiara TA Transapical Mitral Valve Replacement System

Neovasc Files CE Mark for Tiara TA Transapical Mitral Valve Replacement System. TMVR

May 29, 2020 — Neovasc Inc., developer of a minimally invasive transcatheter mitral valve replacement (TMVR) technologies, announced that the company has filed for European CE mark for its Tiara TA Transapical mitral valve replacement system.

Mitral valve disease is one of the most common forms of heart disease that affects millions of patients worldwide. Traditional heart valve replacement surgery requires patients to be placed on a heart-lung bypass machine and results in lengthy recovery time. The Tiara TA transapical mitral valve replacement system uses a percutaneous or “key-hole” incision in the chest to completely replace the native mitral valve and avoids the need for heart-lung bypass. The less invasive approach may allow for more patients to be treated and more rapid recovery.

In April, the European Parliament voted overwhelmingly to extend the Medical Device Directive (MDD) by one year rather than to transition to a new approval process known and the European Medical Device Regulation (MDR). 

“Yesterday we received confirmation from our Notified Body in Europe that the ongoing review of our Tiara application will continue under the MDD regulation.  Now that we have clarity on the regulatory approach, a well-defined pathway, we look forward to continued collaboration with the European authorities,” said Fred Colen, Neovasc CEO.

Tiara is a self-expanding mitral bioprosthesis specifically designed to treat mitral valve regurgitation (MR) by replacing the diseased valve. Conventional surgical treatments are only appropriate for about half of MR patients, who number an estimated four million in the U.S. with a similar number of patients affected throughout Europe. Tiara is implanted in the heart using a minimally invasive, transapical transcatheter approach without the need for open-heart surgery or use of a cardiac bypass machine.

The Tiara valve is not commercially available and is currently being evaluated in two ongoing clinical trials: TIARA-I, an early feasibility trial in the United States, Canada, and Belgium; and TIARA-II, a European Conformité Européenne Mark Trial in Germany, Italy, Spain, and the United Kingdom. In addition, patients have also been treated under compassionate programs in Canada, Italy, Germany, Israel and Switzerland.

For more information: www.neovasc.com
 

Related Content

Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
News | Cath Lab

November 10, 2021 — Shockwave Medical a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely ...

Home November 10, 2021
Home
News | Cath Lab

November 10, 2021 — Philips Healthcare announced North American availability of new innovations in its portfolio of ...

Home November 10, 2021
Home
News | Cath Lab

October 6, 2021 — Boston Scientific Corp. announced it entered into a definitive agreement to acquire Baylis Medical ...

Home October 06, 2021
Home
News | Cath Lab

September 21, 2021 — Medtronic is recalling its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device ...

Home September 21, 2021
Home
Feature | Cath Lab | By Aaron Detate and Lars Thording

In the electrophysiology (EP) lab, hundreds of thousands of used devices are sent to reprocessors every year to get ...

Home September 14, 2021
Home
News | Cath Lab

July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of ...

Home July 22, 2021
Home
Subscribe Now